- ROVI Pharma Industrial Services will collaborate with Roche to manufacture a new medicine in clinical development using a high-speed filling line at its Madrid facility.
- The agreement is expected to drive a 20–25% increase in ROVI’s contract manufacturing business sales by 2030 compared with 2024.
Laboratorios Farmacéuticos Rovi, S.A. (ROVI), a pan-European pharmaceutical company, has announced a collaboration between its subsidiary, ROVI Pharma Industrial Services, S.A.U. (ROIS), and F. Hoffmann-La Roche Ltd. (Roche) for the manufacture of a new medicine currently in clinical development. The product originates from Roche’s metabolic and cardiovascular portfolio.
The final agreement between the two companies is expected to be signed in the coming days, with details to be formally reported to the market once executed.
Under the collaboration, ROIS will make a high-speed filling line available at its facility in San Sebastián de los Reyes, Madrid, to support the production of the new medicine.
ROVI forecasts that the partnership will drive a minimum increase of between 20% and 25% in its contract manufacturing business sales by 2030 compared with 2024 levels.
“We are delighted to become Roche’s strategic partner in the manufacture of this innovative product to be distributed globally and its potential to contribute to enhancing the quality of life of millions of people.” He added that the partnership positions Spain among the leaders in next-generation pharmaceutical production.
Juan López-Belmonte Encina, ROVI’s Chairman and CEO
